Melanie Dart, PhD, is a senior research scientist at Promega Corporation, specializing in translational immunoassay development and biomarker discovery. With a background in clinical immunology and protein biochemistry, Dr. Dart has led the development of proximity-based bioluminescent assays, including applications targeting neurodegenerative biomarkers such as phosphorylated tau. She is a key contributor to Promega’s Lumit® Flex platform and has authored several technical publications and conference presentations on assay optimization in complex biological matrices. Dr. Dart holds a PhD in cellular and molecular pathology from the University of Wisconsin School of Medicine and Public Health and is an advocate for bridging advanced detection technologies into clinically relevant formats.